http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102149734-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2017-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102149734-B1 |
| titleOfInvention | Novel 5H-pyrroro[2,3-d]pyrimidin-6(7H)-one derivative |
| abstract | It provides a novel compound having an inhibitory effect on at least one selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or cell proliferation inhibitory effect. In addition, according to the inhibitory action, at least one selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase is involved, and particularly provides a medicament useful for the prevention and/or treatment of cancer. In the following formula (I), R 1 is a 4 to 6 membered monocyclic having 1 to 3 heteroatoms selected from N, S and O, which may have a substitution group. Is an unsaturated heterocycle group; R 2 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, C2-C6 alkenyl group or C2-C6 alkynyl group; R 3 , R 4 and R 5 are the same or different, and a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 algyl group, C2- Is a C6 alkynyl group; Or R 3 and R 4 together with the nitrogen atom to which they are bound form a 4 to 6 membered monocyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S and O, and R 5 is the same or carried, A hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group; Or R 4 and R 5 together with the nitrogen atom to which they are attached and adjacent carbon atoms form a 4 to 6 membered monocyclic saturated heterocycle having 1 to 3 heteroatoms selected from N, S and O, and R 3 is The same or different, and a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group; R 6 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group or a C2-C6 alkynyl group; R 7 and R 8 are the same or different and are a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group; Or R 7 and R 8 together with the carbon atom to which they are attached form a C3-C10 cycloalkyl group; X 1 and X 2 are the same or different, N or CR 9 , R 9 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alke A nil group, a C2-C6 alkynyl group; X 3 is a broken line ( ) Is N or CH when it is a single bond, and C when the broken line is a double bond. However, when X 1 is CR 9 , X 2 is N, a compound or a salt thereof. [Formula 1] |
| priorityDate | 2016-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 340.